LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, Van De Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 36

Pages Range: 1371-1376

Journal Issue: 5

DOI: 10.1038/s41375-022-01531-2

Abstract

Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.

Involved external institutions

Instituto de Investigación Biomédica de Salamanca (IBSAL) Spain (ES) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Catholic University of the Sacred Heart / Università Cattolica del Sacro Cuore Italy (IT) Universitätsklinikum Heidelberg Germany (DE) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven Belgium (BE) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne France (FR) University of Bologna / Università di Bologna Italy (IT) Washington University in St. Louis United States (USA) (US) Nottingham University Hospitals United Kingdom (GB) Poznan University of Medical Sciences / Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Poland (PL) Ospedale San Martino (IRCCS AOU) Italy (IT) Centre Hospitalier Universitaire (CHU) de Toulouse France (FR) King's College Hospital (KCH) United Kingdom (GB) Vrije Universiteit Amsterdam (VU) / University Amsterdam Netherlands (NL) Universidad de Cantabria (UC) Spain (ES) Universität zu Köln Germany (DE) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) University Medical Center Groningen (UMCG) / Universitair Medisch Centrum Groningen Netherlands (NL) Clínica Universidad de Navarra Spain (ES) Erasmus University Medical Center (MC) Netherlands (NL) Janssen-Cilag France France (FR) Janssen Pharmaceutica NV Belgium (BE) Janssen Global Services, LLC United States (USA) (US) Janssen Biologics BV Netherlands (NL) Legend Biotech USA Inc United States (USA) (US) Universitätsklinikum Würzburg Germany (DE) Nantes University Hospital / Centre hospitalier universitaire de Nantes (CHU) France (FR)

How to cite

APA:

Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M.,... Moreau, P. (2022). LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia, 36(5), 1371-1376. https://doi.org/10.1038/s41375-022-01531-2

MLA:

Mateos, Maria-Victoria, et al. "LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma." Leukemia 36.5 (2022): 1371-1376.

BibTeX: Download